Logic Gated CAR T Reports Durable Isolated Responses
A2 Biotherapeutics provided November 3 follow-up from two small, open-label solid-tumor CAR-T studies. A complete response in one non-small-cell lung cancer patient on EVEREST-2 remains ongoing beyond 12 months; DENALI-1 reported one anal-cancer complete…
